Monocarbonyl curcumin analog A2 potently inhibits angiogenesis by inducing ROS-dependent endothelial cell death.

Authors:
Bin Liu
Bin Liu
National University of Singapore
Singapore | Singapore
Bo Zhou
Bo Zhou
State Key Laboratory of Membrane Biology
China
Ling-Ling Zhang
Ling-Ling Zhang
Anhui Medical University
China
Zhi-Hui Liu
Zhi-Hui Liu
Guangzhou Chest Hospital
Lu Zhang
Lu Zhang
Peking Union Medical College Hospital
China

Acta Pharmacol Sin 2019 Apr 18. Epub 2019 Apr 18.

College of Bioengineering, Henan University of Technology, Zhengzhou, 450001, China.

Excessive and abnormal vessel growth plays a critical role in the pathogenesis of many diseases, such as cancer. Angiogenesis is one of the hallmarks of cancer growth, invasion, and metastasis. Discovery of novel antiangiogenic agents would provide new insights into the mechanisms of angiogenesis, as well as potential drugs for cancer treatment. In the present study, we investigated the antiangiogenic activity of a series of monocarbonyl analogs of curcumin synthesized previously in our lab. We found that curcumin analog A2 displayed the full potential to be developed as a novel antiangiogenic agent. Curcumin analog A2 at and above 20 μM dramatically inhibited the migration and tube formation of human umbilical vein endothelial cells (HUVECs) in vitro, new microvessels sprouting from the rat aortic rings ex vivo and newly formed microvessels in chicken chorioallantoic membranes (CAMs) and Matrigel plus in vivo. We further demonstrated that curcumin analog A2 exerted its antiangiogenic activity mainly through inducing endothelial cell death via elevating NADH/NADPH oxidase-derived ROS. Curcumin analog A2 at the antiangiogenic concentrations also triggered autophagy in HUVECs, but this process is neither a pre-requisite for toxicity, leading to the cell death nor a protective response against the toxicity of curcumin analog A2. In conclusion, we demonstrate for the first time the potent antiangiogenic activity of the monocarbonyl curcumin analog A2, which could serve as a promising potential therapeutic agent for the prevention and treatment angiogenesis-related diseases, such as cancer.

Download full-text PDF

Source
http://www.nature.com/articles/s41401-019-0224-x
Publisher Site
http://dx.doi.org/10.1038/s41401-019-0224-xDOI Listing
April 2019
4 Reads

Article Mentions


Provided by Crossref Event Data
twitter
Twitter:
April 22, 2019, 11:24 am EST

Publication Analysis

Top Keywords

curcumin analog
28
cell death
12
antiangiogenic activity
12
diseases cancer
8
novel antiangiogenic
8
endothelial cell
8
monocarbonyl curcumin
8
curcumin
7
analog
7
antiangiogenic
6
toxicity leading
4
analog 20 μm
4
20 μm dramatically
4
leading cell
4
dramatically inhibited
4
tube formation
4
process pre-requisite
4
human umbilical
4
umbilical vein
4
formation human
4

References

(Supplied by CrossRef)
Article in Cell
M Potente et al.
Cell 2011
Article in Nat Rev Cancer
M Palma De et al.
Nat Rev Cancer 2017
Article in Cancer Sci
K Hida et al.
Cancer Sci 2008
Article in Science
ME Noble et al.
Science 2004
Article in Adv Biomed Res
AH Rahmani et al.
Adv Biomed Res 2018
Article in Curr Vasc Pharmacol
MK Shanmugam et al.
Curr Vasc Pharmacol 2017
Article in Eur J Pharmacol
M El-Azab et al.
Eur J Pharmacol 2011
Article in Biochem Biophys Res Commun
AE Gururaj et al.
Biochem Biophys Res Commun 2002
Article in Foods
SJ Hewlings et al.
Foods 2017
Article in Cancer Science
Kazuhiro Shimazu et al.
Cancer Science 2018
Article in Anticancer Agents Med Chem
S Sugiyama et al.
Anticancer Agents Med Chem 2016

Similar Publications